(7-hydroxy-1,2,3,4-tetrahydro-napthalen-2-yl)-acetic acid ethyl ester | 214401-41-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 四氢化萘
• 英文名称: (7-hydroxy-1,2,3,4-tetrahydro-napthalen-2-yl)-acetic acid ethyl ester
• 英文别名: Ethyl 2-(7-hydroxy-1,2,3,4-tetrahydronaphthalen-2-yl)acetate
• CAS: 214401-41-9
• 化学式: C₁₄H₁₈O₃
• 分子量: 234.295
• InChiKey: OSMCGKDNJDWNOZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (7-hydroxy-1,2,3,4-tetrahydro-napthalen-2-yl)-acetic acid ethyl ester 在 吡啶 、 四(三苯基膦)钯 、 偶氮二异丁腈 、 三正丁基氢锡 、 lithium chloride 作用下， 以 氯仿 为溶剂， 反应 6.0h， 生成 ethyl (E)-{7-[2-(4-cyanophenyl)ethenyl]-1,2,3,4-tetrahydro-2-naphthalenyl}acetate
  参考文献：
  名称：

  New Platelet Fibrinogen Receptor Glycoprotein IIb-IIIa Antagonists:  Orally Active Series of N-Alkylated Amidines with a 6,6-Bicyclic Template

  摘要：

  The design, synthesis, and pharmacological evaluation of (S)-(-)-ethyl [6-[4-(morpholino-formimidoyl)benzamido]-3,4-dihydro-2H-1-benzopyran-3-yl]acetate hydrochloride ((S)-4 . HCl, MS-180), an orally active glycoprotein IIb-IIIa (GPIIb-IIIa) antagonist, are reported. Pharmacophore mapping of amidino and carboxyl groups of already known GPIIb-IIIa antagonists led to the synthesis of nine amidino acids containing 6,6-bicyclic ring skeletons (10a-i). Among them, the compounds 10a,c,e having an amide bond and 1,2,3,4-tetrahydronaphthalene or 3,4-dihydro-2H-1-benzopyran skeleton showed marked inhibitions with IC50 values of 46-57 nM in human platelet aggregation assay in vitro, but low oral activities. N-Alkylation of the amidino group coupled with the ester prodrug approach afforded MS-180 ((S)-4 . HCl), which generates in vivo the corresponding carboxylic acid (S)-3 as an active species. In vitro, (S)-3 inhibited ADP-induced aggregation of guinea pig, dog, and human platelets (IC50 = 110, 253, and 35 nM, respectively) and inhibited the binding of fibrinogen to immobilized GPIIb-IIIa of human platelets (IC50 = 0.12 nM). After oral administration of MS-180 ((S)-4 . HCl) to fasted beagle dog, ex vivo inhibition of platelet aggregation was observed. The maximal inhibitions were observed 2-4 h after dosing with dose dependency (60% inhibition at a dose of 1 mg/kg, 85% at 3 mg/kg, and 100% at 10 mg/kg, respectively) and the extent of the inhibitions paralleled the plasma concentration of the active species (S)-3. On the basis of these studies, we selected MS-180 ((S)-4 . HCl) as a candidate for clinical evaluation as a drug for the treatment and prevention of thrombosis in patients.

  DOI：

  10.1021/jm9801859
• 作为产物：
  描述：

  7-甲氧基-1-萘满酮 在 palladium on activated charcoal sodium tetrahydroborate 、 三甲基氯硅烷 、 氢气 、 4-甲基苯磺酸吡啶 、 sodium hydride 、 碳酸氢钠 、 间氯过氧苯甲酸 、 sodium iodide 、 zinc(II) iodide 作用下， 以 四氢呋喃 、 甲醇 、 乙二醇二甲醚 、 甲苯 、 乙腈 、 苯 为溶剂， 25.0 ℃ 、100.0 kPa 条件下， 反应 19.0h， 生成 (7-hydroxy-1,2,3,4-tetrahydro-napthalen-2-yl)-acetic acid ethyl ester
  参考文献：
  名称：

  New Platelet Fibrinogen Receptor Glycoprotein IIb-IIIa Antagonists:  Orally Active Series of N-Alkylated Amidines with a 6,6-Bicyclic Template

  摘要：

  The design, synthesis, and pharmacological evaluation of (S)-(-)-ethyl [6-[4-(morpholino-formimidoyl)benzamido]-3,4-dihydro-2H-1-benzopyran-3-yl]acetate hydrochloride ((S)-4 . HCl, MS-180), an orally active glycoprotein IIb-IIIa (GPIIb-IIIa) antagonist, are reported. Pharmacophore mapping of amidino and carboxyl groups of already known GPIIb-IIIa antagonists led to the synthesis of nine amidino acids containing 6,6-bicyclic ring skeletons (10a-i). Among them, the compounds 10a,c,e having an amide bond and 1,2,3,4-tetrahydronaphthalene or 3,4-dihydro-2H-1-benzopyran skeleton showed marked inhibitions with IC50 values of 46-57 nM in human platelet aggregation assay in vitro, but low oral activities. N-Alkylation of the amidino group coupled with the ester prodrug approach afforded MS-180 ((S)-4 . HCl), which generates in vivo the corresponding carboxylic acid (S)-3 as an active species. In vitro, (S)-3 inhibited ADP-induced aggregation of guinea pig, dog, and human platelets (IC50 = 110, 253, and 35 nM, respectively) and inhibited the binding of fibrinogen to immobilized GPIIb-IIIa of human platelets (IC50 = 0.12 nM). After oral administration of MS-180 ((S)-4 . HCl) to fasted beagle dog, ex vivo inhibition of platelet aggregation was observed. The maximal inhibitions were observed 2-4 h after dosing with dose dependency (60% inhibition at a dose of 1 mg/kg, 85% at 3 mg/kg, and 100% at 10 mg/kg, respectively) and the extent of the inhibitions paralleled the plasma concentration of the active species (S)-3. On the basis of these studies, we selected MS-180 ((S)-4 . HCl) as a candidate for clinical evaluation as a drug for the treatment and prevention of thrombosis in patients.

  DOI：

  10.1021/jm9801859

文献信息

• Bicyclic antagonists selective for the &agr;v&bgr;3 integrin
  申请人：Wyeth

  公开号：US06429214B1

  公开（公告）日：2002-08-06

  This invention provides novel bicyclic compounds of Formula (I): wherein u, v, m, Y, G, A—B, R1, R1a, R2, R4, R5, R5a, and R5b are defined in the specification which compounds exhibit activity as inhibitors of bone resorption and compounds of Formula (II) wherein u, v, m, Y, G, D, A—B, R1, R1a, R2, R3, R4, R5, R5a, and R5b are defined in the specification which compounds exhibit activity as inhibitors of bone resorption.

  这项发明提供了式（I）的新颖双环化合物：其中u、v、m、Y、G、A—B、R1、R1a、R2、R4、R5、R5a和R5b在规范中定义，这些化合物表现出作为骨吸收抑制剂的活性；以及式（II）的化合物：其中u、v、m、Y、G、D、A—B、R1、R1a、R2、R3、R4、R5、R5a和R5b在规范中定义，这些化合物表现出作为骨吸收抑制剂的活性。
• Bicyclic antagonists selective for the alphavbeta3 integrin
  申请人：Wyeth

  公开号：US20030109523A1

  公开（公告）日：2003-06-12

  This invention provides novel bicyclic compounds of Formula (I): 1 wherein u, v, m, Y, G, A-B, R 1 , R 1a , R 2 , R 4 , R 5 , R 5a , and R 5b are defined in the specification which compounds exhibit activity as inhibitors of bone resorption and compounds of Formula (II) 2 wherein u, v, m, Y, G, D, A-B, R 1 , R 1a , R 2 , R 3 R 4 , R 5 , R 5a , and R 5b are defined in the specification which compounds exhibit activity as inhibitors of bone resorption.

  这项发明提供了公式（I）的新型双环化合物：其中u、v、m、Y、G、A-B、R1、R1a、R2、R4、R5、R5a和R5b在规范中有定义，这些化合物表现出抑制骨吸收的活性，以及公式（II）的化合物：其中u、v、m、Y、G、D、A-B、R1、R1a、R2、R3、R4、R5、R5a和R5b在规范中有定义，这些化合物也表现出抑制骨吸收的活性。
• 一种并环类衍生物及其制备方法和医药用途
  申请人：深圳信立泰药业股份有限公司

  公开号：CN115594669A

  公开（公告）日：2023-01-13

  本发明属于化学药物技术领域，涉及式(I)的化合物、其制备方法及其在医药上的应用。具体而言，本发明提供式(I)的化合物或其立体异构体、互变异构体、药学上可接受的盐。这些化合物是胰高血糖样肽‑1受体(GLP‑1R)的激动剂。本发明还涉及包含这些化合物的药物组合物以及使用该化合物治疗糖尿病等疾病的药物中的用途。
• BICYCLIC ANTAGONISTS SELECTIVE FOR THE(ALPHA)V(BETA)3 INTEGRIN
  申请人：AMERICAN HOME PRODUCTS CORPORATION

  公开号：EP1198231A1

  公开（公告）日：2002-04-24
• US6429214B1
  申请人：——

  公开号：US6429214B1

  公开（公告）日：2002-08-06